Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities

Blood (2025) 146 (Supplement 1): 3.

https://doi.org/10.1182/blood-2025-3

Published: 2025

Journal Articles

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 3709.

https://doi.org/10.1182/blood-2025-3709

Published: 2025

Journal Articles

Epigenetically driven upregulation of immunoproteasome component PSMB8 characterizes diffuse large B-cell lymphoma (DLBCL) with inflammatory microenvironment in African ancestry patients

María Revuelta, Ines Mota, Vishal Sahu, Tania Sainz, Kumudha Balakrishnan, Federico Ruiz Moreno, Nahuel Zamponi, Francisco Vega, Christopher Flowers, Leandro Cerchietti

Blood (2025) 146 (Supplement 1): 3674.

https://doi.org/10.1182/blood-2025-3674

Published: 2025

Journal Articles

A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies

Blood (2025) 146 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2025-2337

Published: 2025

Journal Articles

KIR3DL2-directed CAR T cell therapy for T cell malignancies

Blood (2025) 146 (Supplement 1): 7621.

https://doi.org/10.1182/blood-2025-7621

Published: 2025

Journal Articles

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Neha Akkad, Amy Ayers, Kumudha Balakrishnan, Loretta Nastoupil, Dai Chihara, Luis Malpica, Paolo Strati, Ziyi Li, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2024-201804

Published: 2024

Journal Articles

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Jean L. Koff, Kumudha Balakrishnan, Michael Churnetski, Michelle J. Lee, Anna Kurilovich, Svetlana Paponova, Alexander Nesmelov, Ksenia Zornikova, Pavel Zemskiy, Alexander Bagaev, Nikita Kotlov, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2024-209996

Published: 2024

Journal Articles

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Michelle J. Lee, Kumudha Balakrishnan, Pavel Zemskiy, James D. Ayres, Timothy J. McDonnell, Neha Akkad, Kiril Kriukov, Arina Tkachuk, Ksenia Zornikova, Krystle Nomie, Aleksander Bagaev, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2024-210739

Published: 2024

Journal Articles

Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Michelle J. Lee, Kumudha Balakrishnan, Arman Petrosyants, Daniil Wiebe, Chijioke Nze, Neha Akkad, Amy Ayers, James D. Ayres, Timothy J. McDonnell, Pavel Zemskiy, Kiril Kriukov, Alexander Nesmelov, Ksenia Zornikova, Krystle Nomie, Alexander Sarachakov, Nikita Kotlov, Ankur Singh, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4348.

https://doi.org/10.1182/blood-2024-210184

Published: 2024

Journal Articles

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Tony Z. Zhuang, Lei Feng, Dai Chihara, Chijioke Nze, Amy A. Ayers, Mansoor Noorani, James D. Ayres, Daniela E. Duenas, Kumudha Balakrishnan, Ekaterina Nesterenko, Mark Meerson, Ksenia Zornikova, Krystle Nomie, Nikita Kotlov, Nathan Fowler, Maria Alma Rodriguez, Sattva S. Neelapu, Christopher R. Flowers, Paolo Strati

Blood (2024) 144 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2024-202654

Published: 2024

Journal Articles

Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4364.

https://doi.org/10.1182/blood-2024-209105

Published: 2024

Journal Articles

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev, Nikita Kotlov, Ekaterina Postovalova, Eduardo Shugaev-Mendosa, Yuliya Gracheva, Anna Love, Krystle Nomie, Nathan Fowler, Christopher R. Flowers, Jason Westin

Blood (2023) 142 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2023-189426

Published: 2023

Journal Articles

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells

Viralkumar Patel, Kumudha Balakrishnan, Michael J. Keating, William G. Wierda, Varsha Gandhi

Blood (2015) 125 (7): 1126–1136.

https://doi.org/10.1182/blood-2014-01-546796

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Kumudha Balakrishnan, Marisa Peluso, Min Fu, Nathalie Y. Rosin, PhD, Jan A. Burger, MD, PhD, William G. Wierda, MD, PhD, Michael J. Keating, MD, Kerrie Faia, MS, Susan O'Brien, MD, Jeff Kutok, Karen McGovern, PhD, Varsha Gandhi, PhD

Blood (2013) 122 (21): 4167.

https://doi.org/10.1182/blood.V122.21.4167.4167

Published: 2013

Journal Articles

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Blood (2013) 122 (21): 4169.

https://doi.org/10.1182/blood.V122.21.4169.4169

Published: 2013

Journal Articles

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, M.D., Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, Michael J. Keating, MD, Varsha V. Gandhi, Ph.D.

Blood (2012) 120 (21): 437.

https://doi.org/10.1182/blood.V120.21.437.437

Published: 2012

Journal Articles

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Sabine Ponader, Shih-Shih Chen, Joseph J. Buggy, Kumudha Balakrishnan, Varsha Gandhi, William G. Wierda, Michael J. Keating, Susan O'Brien, Nicholas Chiorazzi, Jan A. Burger

Blood (2012) 119 (5): 1182–1189.

https://doi.org/10.1182/blood-2011-10-386417

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, MD, Tapan Kadia, Jorge E. Cortes, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, BA, Michael J Keating, MD, Varsha Gandhi, PhD

Blood (2011) 118 (21): 3901.

https://doi.org/10.1182/blood.V118.21.3901.3901

Published: 2011

Journal Articles

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Kumudha Balakrishnan, Jan A. Burger, Maite P. Quiroga, Marina Henneberg, Mary L. Ayres, William G. Wierda, Varsha Gandhi

Blood (2010) 116 (7): 1083–1091.

https://doi.org/10.1182/blood-2009-10-246199

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Kumudha Balakrishnan, Dushyant Verma, Susan O'Brien, John Michael Kilpatrick, Yuling Chen, Brenita F. Tyler, Susan Bickel, Shanta Bantia, Michael J. Keating, Hagop Kantarjian, Varsha Gandhi, Farhad Ravandi

Blood (2010) 116 (6): 886–892.

https://doi.org/10.1182/blood-2010-02-272039

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities

Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy

Epigenetically driven upregulation of immunoproteasome component PSMB8 characterizes diffuse large B-cell lymphoma (DLBCL) with inflammatory microenvironment in African ancestry patients

A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies

KIR3DL2-directed CAR T cell therapy for T cell malignancies

Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only